# Acerand Therapeutics

Source: https://onco.cc/companies/acerand-therapeutics/  
OnCo record `acerand-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Acerand Therapeutics develops small-molecule cancer medicines. Its programmes include ACE-232, a tablet that blocks the CYP11A1 enzyme at the start of steroid hormone production, in an early trial for prostate cancer that no longer responds to hormone therapy, and a selective PARP1 inhibitor.

## Summary

Acerand Therapeutics lists addresses in Shanghai and Carmel, Indiana, and says it concentrates its drug discovery on oncology small molecules; its site says it was founded by industry veterans with LAV. ACE-232 is a CYP11A1 inhibitor: the FDA cleared it for clinical investigation in January 2025, the first-in-human phase 1 trial NCT06801236 in metastatic castration-resistant prostate cancer (given with dexamethasone and fludrocortisone, at US and Chinese sites) began in 2025, and China's CDE cleared a study in July 2025. The company also reported first patient enrolment in a phase 1/2 trial of a selective PARP1 inhibitor in March 2024 and preliminary clinical data in May 2025, and an update on ACE-106 in April 2026. Its first cancer trial registered under the sponsor name Acerand Therapeutics (Hong Kong) Limited, NCT06801236, was posted on ClinicalTrials.gov in January 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: 优领医药
- HQ: Shanghai
- Type: biotech
- Website: https://www.acerand.com/

## Notes

- Founding year not stated on the company website (footer reads 2021).
- No financing amounts are stated on the company website; LAV is not explained there, so no investor is listed.
- The pipeline page is an image and was not read; ACE-106's target is not recorded.
- Company website and news page read on 29 October 2026.

## Sources

- Official website: https://www.acerand.com/
- Acerand Therapeutics news: https://www.acerand.com/news.html
- ClinicalTrials.gov: phase 1 trial of ACE-232 in mCRPC (NCT06801236): https://clinicaltrials.gov/study/NCT06801236

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [CYP11A1 (cholesterol side-chain cleavage enzyme)](https://onco.cc/targets/cyp11a1/), [PARP](https://onco.cc/targets/parp/)

---
JSON: https://onco.cc/api/v1/entities/acerand-therapeutics.json